<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of pericardial disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of pericardial disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of pericardial disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian D Hoit, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin M LeWinter, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H982115581"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The pericardium is a fibroelastic sac surrounding the heart that contains a small physiologic amount of fluid (15 to 50 mL). Pericardial diseases are relatively common in clinical practice as either isolated disease or as a manifestation of a systemic disorder. An overview of clinical syndromes associated with pericardial disease is presented here.</p><p class="headingAnchor" id="H1509090032"><span class="h1">CLASSIFICATION OF PERICARDIAL SYNDROMES</span><span class="headingEndMark"> — </span>Pericardial syndromes are classified according to clinical features, time course, and etiology  (<a class="graphic graphic_table graphicRef67851" href="/z/d/graphic/67851.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef61171" href="/z/d/graphic/61171.html" rel="external">table 2</a>). The main syndromes are [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute, recurrent, incessant, and chronic pericarditis</strong> – (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4944.html" rel="external">"Recurrent pericarditis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pericardial effusion</strong> – (See  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With hemodynamic compromise (cardiac tamponade). (See  <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Without hemodynamic compromise. (See  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis", section on 'Hemodynamic effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constrictive pericarditis</strong> – (See  <a class="medical medical_review" href="/z/d/html/140205.html" rel="external">"Constrictive pericarditis: Clinical features and causes"</a> and  <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation"</a>.)</p><p></p><p>There is overlap among clinical syndromes. For example, some patients presenting with acute, recurrent, or chronic pericarditis have pericardial effusion. Also, some patients presenting with pericardial effusion have constrictive pericarditis, and thus have effusive-constrictive pericarditis. (See <a class="local">'Effusive-constrictive pericarditis'</a> below.)</p><p class="headingAnchor" id="H1241994671"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The etiology of pericardial disease can be classified into the following categories  (<a class="graphic graphic_table graphicRef67851" href="/z/d/graphic/67851.html" rel="external">table 1</a>) [<a href="#rid2">2,3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic </strong>(presumed to be viral or immune-mediated [<a href="#rid4">4,5</a>]), which typically presents as acute pericarditis. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious</strong> – Nearly any infectious organism can infect the pericardium. While most types of pericardial infection present with acute pericarditis and/or pericardial effusion, some pericardial bacterial or fungal infections present with purulent pericarditis, defined as infection with macroscopically or microscopically purulent pericardial fluid. (See  <a class="medical medical_review" href="/z/d/html/2128.html" rel="external">"Purulent pericarditis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Viral</strong> – Includes coxsackievirus (types A and B), echovirus, adenovirus, Epstein-Barr virus, cytomegalovirus, herpes, influenza, varicella, rubella, human immunodeficiency virus (HIV), hepatitis B, mumps, parvovirus B19, vaccina (<a class="drug drug_general" data-topicid="10175" href="/z/d/drug information/10175.html" rel="external">smallpox vaccine</a>), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bacterial</strong> – Includes <em>Mycobacterium tuberculosis </em>(see  <a class="medical medical_review" href="/z/d/html/8002.html" rel="external">"Tuberculous pericarditis"</a>), <em>Staphylococcus</em>, <em>Streptococcus</em>, <em>Haemophilus</em>, <em>Neisseria</em> (<em>N. gonorrhoeae</em> or <em>N. meningitidis</em>), <em>Chlamydia</em> (<em>C. psittaci</em> or <em>C. trachomatis</em>), <em>Legionella</em>, <em>Pneumococcus</em>, <em>Salmonella</em>, <em>Borrelia</em> <em>burgdorferi</em>, <em>Mycoplasma</em>, <em>Actinomyces</em>, <em>Nocardia</em>, <em>Tropheryma</em> <em>whipplei</em>, <em>Treponema</em>, <em>Rickettsia</em>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fungal</strong> – Includes <em>Histoplasma</em>, <em>Aspergillus</em>, <em>Blastomyces</em>, <em>Coccidioides</em>, <em>Candida.</em> (See  <a class="medical medical_review" href="/z/d/html/2436.html" rel="external">"Candida infections of the abdomen and thorax", section on 'Pericarditis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Parasitic</strong> – Includes <em>Echinococcus</em>, amebic, <em>Toxoplasma</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune and autoinflammatory</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systemic inflammatory diseases</strong> (eg, systemic lupus erythematosus, rheumatoid arthritis). (See  <a class="medical medical_review" href="/z/d/html/16578.html" rel="external">"Pericardial involvement in systemic autoimmune diseases"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autoinflammatory conditions</strong> (eg, familial Mediterranean fever, tumor necrosis factor associated periodic syndrome [TRAPS], IgG4-related disease). (See  <a class="medical medical_review" href="/z/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever", section on 'Chest pain'</a> and  <a class="medical medical_review" href="/z/d/html/5580.html" rel="external">"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/121220.html" rel="external">"Clinical manifestations and diagnosis of IgG4-related disease", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Post-cardiac injury syndrome</strong>, which includes (see  <a class="medical medical_review" href="/z/d/html/4915.html" rel="external">"Post-cardiac injury syndromes"</a>):</p><p class="bulletIndent3"><span class="glyph">-</span>Post-myocardial infarction</p><p class="bulletIndent3"><span class="glyph">-</span>Postpericardiotomy</p><p class="bulletIndent3"><span class="glyph">-</span>Posttraumatic (including iatrogenic)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – Includes granulomatosis with polyangiitis, polyarteritis nodosa, sarcoidosis, inflammatory bowel disease (Crohn, ulcerative colitis), giant cell arteritis, Behçet syndrome, rheumatic fever. (See  <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a> and  <a class="medical medical_review" href="/z/d/html/91259.html" rel="external">"Overview of extrapulmonary manifestations of sarcoidosis", section on 'Cardiovascular'</a> and  <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2702.html" rel="external">"Whipple's disease"</a> and  <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis"</a> and  <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">"Clinical manifestations and diagnosis of Behçet syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/3177.html" rel="external">"Acute rheumatic fever: Clinical manifestations and diagnosis", section on 'Carditis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neoplasm</strong> – Including lung and breast cancer, Hodgkin lymphoma, and mesothelioma. (See  <a class="medical medical_review" href="/z/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trauma</strong> – Blunt or penetrating (including iatrogenic injury). (See  <a class="medical medical_review" href="/z/d/html/359.html" rel="external">"Initial evaluation and management of blunt cardiac injury"</a> and  <a class="medical medical_review" href="/z/d/html/13862.html" rel="external">"Initial evaluation and management of penetrating thoracic trauma in adults", section on 'Cardiac injury'</a> and  <a class="medical medical_review" href="/z/d/html/4915.html" rel="external">"Post-cardiac injury syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic</strong> (uremia, dialysis-associated, hypothyroidism, ovarian hyperstimulation syndrome). (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Pericarditis'</a> and  <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism", section on 'Cardiovascular system'</a> and  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation</strong> – Most cases are secondary to radiation therapy for Hodgkin lymphoma, breast cancer, or lung cancer. Improved shielding and dose calculation have reduced the incidence of this complication. (See  <a class="medical medical_review" href="/z/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs and toxins</strong>  (<a class="graphic graphic_table graphicRef61171" href="/z/d/graphic/61171.html" rel="external">table 2</a>)</p><p></p><p class="headingAnchor" id="H3465905327"><span class="h1">PERICARDITIS</span><span class="headingEndMark"> — </span>Pericarditis refers to inflammation of the pericardial sac and is the most common pericardial disorder.</p><p class="headingAnchor" id="H468943568"><span class="h2">Pericarditis syndromes</span></p><p class="headingAnchor" id="H813451580"><span class="h3">Acute pericarditis</span></p><p class="headingAnchor" id="H1528676243"><span class="h4">Clinical features</span><span class="headingEndMark"> — </span>Acute pericarditis is a condition (with or without pericardial effusion) lasting less than four to six weeks with at least two of the following criteria  (<a class="graphic graphic_table graphicRef74376" href="/z/d/graphic/74376.html" rel="external">table 3</a>) [<a href="#rid1">1,6</a>] (see  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Typical chest pain (sharp and pleuritic, improved by sitting up and leaning forward).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial friction rub (a superficial scratchy or squeaking sound best heard with the diaphragm of the stethoscope over the left sternal border)  (<a class="graphic graphic_movie graphicRef56608" href="/z/d/graphic/56608.html" rel="external">movie 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Characteristic changes on the electrocardiogram (ECG; typically widespread ST-segment elevation)  (<a class="graphic graphic_waveform graphicRef77572" href="/z/d/graphic/77572.html" rel="external">waveform 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New or worsening pericardial effusion.</p><p></p><p>In resource-abundant countries, the cause of acute pericarditis is often unknown (idiopathic) and is presumed to be caused by a virus or immune response to a virus  (<a class="graphic graphic_table graphicRef60949" href="/z/d/graphic/60949.html" rel="external">table 4</a>). In resource-limited countries, the most common cause of acute pericarditis is tuberculosis. (See  <a class="medical medical_review" href="/z/d/html/8002.html" rel="external">"Tuberculous pericarditis"</a>.)</p><p class="headingAnchor" id="H2847428629"><span class="h4">Prognosis</span><span class="headingEndMark"> — </span>While most patients with acute idiopathic or viral pericarditis have a good long-term prognosis, a minority of patients develop recurrent or incessant disease and are at risk for developing constrictive pericarditis. (See <a class="local">'Recurrent pericarditis'</a> below and <a class="local">'Incessant and chronic pericarditis'</a> below and <a class="local">'Risk of constrictive pericarditis after acute pericarditis'</a> below.)</p><p class="headingAnchor" id="H2562047092"><span class="h3">Recurrent pericarditis</span><span class="headingEndMark"> — </span>Recurrent pericarditis is identified as recurrence of symptoms of acute pericarditis after a symptom-free interval of least four to six weeks [<a href="#rid7">7,8</a>]. Four to six weeks has been established as the minimum required symptom-free interval as it represents the typical duration of antiinflammatory therapy (including taper). The recurrence rate for idiopathic acute pericarditis may be as high as 37 percent in patients not treated with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> and 15 percent for those treated with colchicine [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Colchicine'</a>.)</p><p class="headingAnchor" id="H400182760"><span class="h3">Incessant and chronic pericarditis</span><span class="headingEndMark"> — </span>Pericarditis is categorized as incessant when symptoms and signs persist for greater than four to six weeks up to three months without a sustained remission [<a href="#rid7">7</a>]. This includes recurrence of symptoms after a symptom-free interval of less than four to six weeks after the acute episode. Such recurrences often occur during attempted drug weaning, particularly following glucocorticoid therapy; they are less common following nonsteroidal antiinflammatory drug (NSAID) use.</p><p>Chronic pericarditis is defined as occurring when symptoms persist for greater than three months [<a href="#rid7">7</a>].</p><p>Cholesterol pericarditis is a complication of chronic pericardial effusion exacerbated by cholesterol crystals. Causes include tuberculous pericarditis , rheumatoid pericarditis, and pericardial trauma, a less common cause. (See  <a class="medical medical_review" href="/z/d/html/8002.html" rel="external">"Tuberculous pericarditis"</a> and  <a class="medical medical_review" href="/z/d/html/16578.html" rel="external">"Pericardial involvement in systemic autoimmune diseases", section on 'Rheumatoid arthritis'</a> and  <a class="medical medical_review" href="/z/d/html/4915.html" rel="external">"Post-cardiac injury syndromes"</a>.)</p><p>Incessant pericarditis and chronic pericarditis are associated with an increased risk of developing constrictive pericarditis. (See <a class="local">'Constrictive pericarditis'</a> below.)</p><p class="headingAnchor" id="H437108600"><span class="h3">Myopericarditis</span><span class="headingEndMark"> — </span>While the terms myopericarditis and perimyocarditis are often used interchangeably, the terms represent two different disease processes with distinct approaches to diagnosis and treatment.</p><p class="bulletIndent1"><span class="glyph">●</span>"Myopericarditis" refers to cases of confirmed acute pericarditis with elevated troponin but without left ventricular systolic dysfunction. (See  <a class="medical medical_review" href="/z/d/html/4930.html" rel="external">"Myopericarditis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"Perimyocarditis" refers to cases presenting as acute pericarditis with elevated troponin and left ventricular ejection fraction less than 55 percent. The diagnostic approach and management for perimyocarditis is the same as for myocarditis. (See  <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">"Treatment and prognosis of myocarditis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2550406997"><span class="h2">Management of pericarditis</span></p><p class="headingAnchor" id="H834887214"><span class="h3">General measures and treatment of cause</span><span class="headingEndMark"> — </span>Management of pericarditis includes effective communication with the patient about the disease course and therapy directed at the disease process or cause (if known)  (<a class="graphic graphic_algorithm graphicRef114845" href="/z/d/graphic/114845.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>For inflammatory conditions</strong> – Most patients with acute or recurrent pericarditis are treated with antiinflammatory agents  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 5</a>), including those with the following clinical presentations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute or recurrent pericarditis which is idiopathic (presumed immune reaction to viral infection). However, when an ongoing viral infection is confirmed, glucocorticoid therapy is avoided [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent2">Management of acute pericarditis during pregnancy is modified to take into consideration the impact of medical therapies on the fetus. (See  <a class="medical medical_review" href="/z/d/html/4934.html" rel="external">"Management of pericardial effusion and acute pericarditis during pregnancy", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute pericarditis caused by radiation therapy. (See  <a class="medical medical_review" href="/z/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis", section on 'Radiation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Post-cardiac injury syndromes (post-myocardial infarction syndrome, postpericardiotomy syndrome, posttraumatic pericarditis). (See  <a class="medical medical_review" href="/z/d/html/4915.html" rel="external">"Post-cardiac injury syndromes", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent2">The role of prophylactic <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> following cardiac surgery to reduce the risk of postpericardiotomy syndrome is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4915.html" rel="external">"Post-cardiac injury syndromes", section on 'Colchicine'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with systemic autoimmune disease with asymptomatic pericardial involvement are generally treated with standard therapy for their autoimmune condition. Those who develop symptomatic acute pericarditis are generally treated with antiinflammatory therapy  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/16578.html" rel="external">"Pericardial involvement in systemic autoimmune diseases", section on 'Clinical presentation, diagnosis, and treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For uremia</strong> - Management of uremic pericarditis involves initiation or intensification of dialysis. Dialysis alone may improve chest pain associated with pericarditis and decrease the size of the pericardial effusion, particularly in patients recently initiating dialysis. When pharmacologic therapy is required, treatment is similar to that for patients without chronic kidney disease. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Treatment in patients with chronic kidney disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For infection</strong> – Management involves treatment with the appropriate antimicrobial agent. Purulent pericarditis requires urgent management, as discussed below. (See <a class="local">'Urgent conditions'</a> below.)</p><p></p><p class="headingAnchor" id="H3647068901"><span class="h3">Pericardiectomy</span><span class="headingEndMark"> — </span>Pericardiectomy is an option for patients with recurrent pericarditis who have persistent symptoms after failure of medical regimens  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 5</a>) including NSAID or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, and glucocorticoid therapy. In this setting, the potential benefits and risks of immune therapy (eg, interleukin-1 inhibitor [<a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">rilonacept</a> or <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>]) and of pericardiectomy (as an alternative to drug therapy) are discussed with the patient. (See  <a class="medical medical_review" href="/z/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H3194713976"><span class="h1">PERICARDIAL EFFUSION</span><span class="headingEndMark"> — </span>A pericardial effusion is present when accumulated fluid within the sac exceeds the small physiologic amount (15 to 50 mL). Pericardial effusions are caused by a wide range of diseases  (<a class="graphic graphic_table graphicRef67851" href="/z/d/graphic/67851.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef78847" href="/z/d/graphic/78847.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p class="headingAnchor" id="H170307063"><span class="h2">Urgent conditions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac tamponade</strong> – Cardiac tamponade requires urgent diagnosis and management. It is caused by pericardial fluid accumulating under pressure, impairing cardiac filling and reducing stroke volume. Tamponade is suspected based upon the patient's history (which may include a cause of pericardial disease), symptoms (eg, fatigue, dyspnea, syncope, presyncope), and signs. Nearly all patients with cardiac tamponade have at least one of the following findings: sinus tachycardia, elevated jugular venous pressure (which may not be present in severely hypovolemic patients), pulsus paradoxus, and hypotension. (See  <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p></p><p class="bulletIndent1">With cardiac tamponade, the pericardial effusion is usually moderate or large  (<a class="graphic graphic_movie graphicRef66715" href="/z/d/graphic/66715.html" rel="external">movie 2</a>) but may be surprisingly small if the effusion has accumulated rapidly. The speed of pericardial fluid accumulation affects the size of pericardial effusion that causes cardiac tamponade  (<a class="graphic graphic_figure graphicRef75068" href="/z/d/graphic/75068.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Purulent pericarditis</strong> – Purulent pericarditis (defined as infection with macroscopically or microscopically purulent pericardial fluid) requires urgent diagnosis and management. It typically presents with high fever and tachycardia with or without chest pain, often in the setting of predisposing conditions. (See  <a class="medical medical_review" href="/z/d/html/2128.html" rel="external">"Purulent pericarditis"</a>.)</p><p></p><p class="bulletIndent1">Purulent pericarditis may be caused by bacterial (including tuberculous) and fungal infection. It is treated with urgent pericardial fluid removal (pericardiocentesis when feasible and/or surgical pericardial fluid drainage with window to prevent hemodynamic compromise) and antimicrobial therapy. (See  <a class="medical medical_review" href="/z/d/html/2128.html" rel="external">"Purulent pericarditis", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/2436.html" rel="external">"Candida infections of the abdomen and thorax", section on 'Pericarditis'</a> and  <a class="medical medical_review" href="/z/d/html/8002.html" rel="external">"Tuberculous pericarditis", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H642237674"><span class="h2">Other clinical presentations</span><span class="headingEndMark"> — </span>Many patients with pericardial effusion without tamponade have no symptoms or signs directly caused by the pericardial effusion, although they may have symptoms related to the underlying cause of pericardial disease (eg, fever in the setting of infectious or immune-mediated pericarditis). Thus, pericardial effusions are often discovered incidentally during evaluation for other cardiopulmonary and noncardiopulmonary diseases. (See  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis", section on 'When to suspect pericardial effusion'</a>.)</p><p>Treatment of chylopericardium including dietary therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4917.html" rel="external">"Chylopericardium and cholesterol pericarditis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2137602585"><span class="h2">Diagnostic evaluation</span><span class="headingEndMark"> — </span>Most pericardial effusions are identified by transthoracic echocardiogram (TTE), which also enables assessment of the hemodynamic effects of the effusion (determination of whether it is causing cardiac tamponade) and provides an estimate of its size. (See  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis", section on 'Echocardiography'</a> and  <a class="medical medical_review" href="/z/d/html/5299.html" rel="external">"Echocardiographic evaluation of the pericardium"</a>.)</p><p>In some cases, the likely cause of the pericardial effusion will be evident from the clinical context (eg, malignant pericardial disease in a patient with lung cancer). If the cause is not apparent, evaluation of the pericardial fluid (with or without biopsy) may suggest an etiology  (<a class="graphic graphic_table graphicRef78847" href="/z/d/graphic/78847.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis", section on 'Pericardial fluid analysis and biopsy'</a>.)</p><p class="headingAnchor" id="H915831844"><span class="h2">Management of pericardial effusion</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for drainage</strong> – Urgent pericardial fluid removal is required for patients with cardiac tamponade and for patients with purulent pericarditis  (<a class="graphic graphic_algorithm graphicRef143187" href="/z/d/graphic/143187.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">"Cardiac tamponade"</a> and  <a class="medical medical_review" href="/z/d/html/2128.html" rel="external">"Purulent pericarditis"</a>.)</p><p></p><p class="bulletIndent1">Patients who do not require immediate pericardial fluid drainage are monitored; some may undergo pericardial fluid sampling for diagnostic purposes. (See  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis", section on 'Pericardial fluid analysis and biopsy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of procedure</strong> – When pericardial fluid drainage is indicated, the choice of procedure is based largely upon whether the pericardial effusion is accessible to percutaneous drainage and whether there is a critical cardiac or aortic bleeding site that requires surgical management  (<a class="graphic graphic_algorithm graphicRef143187" href="/z/d/graphic/143187.html" rel="external">algorithm 2</a>) [<a href="#rid1">1</a>]. In patients with cardiac tamponade, invasive hemodynamic monitoring during the pericardial drainage procedure enables definitive confirmation of cardiac tamponade. (See  <a class="medical medical_review" href="/z/d/html/143123.html" rel="external">"Pericardial effusion: Approach to management", section on 'Choice of pericardial drainage procedure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring and treatment of cause</strong> – Patients in whom the initial approach is observation (or who have undergone pericardiocentesis) should undergo serial clinical and echocardiographic evaluation, avoid volume depletion, and receive treatment for the underlying cause of the pericardial effusion, if known. (See  <a class="medical medical_review" href="/z/d/html/143123.html" rel="external">"Pericardial effusion: Approach to management", section on 'General management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and treatment of recurrent effusion</strong> – For patients deemed at high risk for recurrent pericardial effusion (including those with malignant pericardial effusion, purulent pericarditis, or cholesterol pericarditis), initial management with pericardial fluid removal may be combined with or followed by one or more measures to prevent or treat recurrent pericardial effusion, such as prolonged catheter drainage, repeated pericardiocentesis, surgical pericardiotomy (pericardial window), or pericardiectomy (for cholesterol pericarditis) along with treatment of the underlying cause of the effusion (eg, chemotherapy for malignancy). (See  <a class="medical medical_review" href="/z/d/html/143123.html" rel="external">"Pericardial effusion: Approach to management", section on 'Management of recurrent pericardial effusion'</a> and  <a class="medical medical_review" href="/z/d/html/141940.html" rel="external">"Pericardial disease associated with cancer: Management", section on 'Prevention and treatment of recurrent malignant pericardial effusion'</a> and  <a class="medical medical_review" href="/z/d/html/4917.html" rel="external">"Chylopericardium and cholesterol pericarditis", section on 'Cholesterol pericarditis'</a>.)</p><p></p><p class="headingAnchor" id="H2005624311"><span class="h1">CONSTRICTIVE PERICARDITIS</span></p><p class="headingAnchor" id="H2053102349"><span class="h2">Clinical presentation and diagnosis</span><span class="headingEndMark"> — </span>Constrictive pericarditis is a clinical syndrome in which an inelastic thickened pericardium restricts cardiac filling [<a href="#rid1">1,6,10</a>]. Constrictive pericarditis should be suspected in any patient with symptoms and signs consistent with the diagnosis (such as dyspnea on exertion, peripheral edema, and unexplained elevation of jugular venous pressure with prominent y descent  (<a class="graphic graphic_figure graphicRef80995" href="/z/d/graphic/80995.html" rel="external">figure 2</a>)), particularly if there is a history of a predisposing condition such as malignancy, prior cardiac surgery, prior radiation therapy, or prior purulent pericarditis. Patients with constrictive pericarditis typically present months to years after an initial insult involving the pericardium. (See  <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation", section on 'When to suspect constrictive pericarditis'</a>.)</p><p class="headingAnchor" id="H516049363"><span class="h2">Risk of constrictive pericarditis after acute pericarditis</span><span class="headingEndMark"> — </span>The risk of developing constrictive pericarditis after acute pericarditis varies depending on the cause of acute pericarditis, with low risk (0.76/1000 person-years) in patients with idiopathic/viral cause, higher risk in patients with pericardial injury syndrome or systemic autoimmune disorders (4.4/1000 person-years) or neoplasm (6.33/1000 person-years), and highest risk (52.74/1000 person-years) with purulent pericarditis (including tuberculous pericarditis, 31.65/1000 person-years), as discussed separately [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/140205.html" rel="external">"Constrictive pericarditis: Clinical features and causes", section on 'Incidence and causes'</a>.)</p><p>The cause of acute pericarditis that precedes constrictive pericarditis varies widely depending on the population studied, with idiopathic or posttreatment (eg, postoperative or postradiation) causes being more common in resource-abundant countries and infectious etiologies (tuberculosis) being more prominent in resource-limited countries. (See  <a class="medical medical_review" href="/z/d/html/140205.html" rel="external">"Constrictive pericarditis: Clinical features and causes", section on 'Incidence and causes'</a>.)</p><p class="headingAnchor" id="H1946891620"><span class="h2">Transient constrictive pericarditis</span><span class="headingEndMark"> — </span>In a minority of cases of constrictive pericarditis, the constriction resolves spontaneously or with medical therapy, with most such cases resolving within two to six months with antiinflammatory therapy  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 5</a> and <a class="graphic graphic_algorithm graphicRef141073" href="/z/d/graphic/141073.html" rel="external">algorithm 3</a>). Cases of transient (subacute) constrictive pericarditis commonly present as effusive-constrictive pericarditis. (See  <a class="medical medical_review" href="/z/d/html/140205.html" rel="external">"Constrictive pericarditis: Clinical features and causes", section on 'Transient constrictive pericarditis'</a>.)</p><p class="headingAnchor" id="H3063120664"><span class="h2">Chronic constrictive pericarditis</span><span class="headingEndMark"> — </span>Most constrictive pericarditis has a chronic course, with constriction persisting for greater than three to six months. Chronic constrictive pericarditis which is manifested by anasarca, atrial fibrillation, hepatic dysfunction, and/or pericardial calcification. Pericardial effusion is rarely a prominent feature of chronic constrictive pericarditis. (See  <a class="medical medical_review" href="/z/d/html/140205.html" rel="external">"Constrictive pericarditis: Clinical features and causes", section on 'Constrictive pericarditis'</a>.)</p><p class="headingAnchor" id="H1725946131"><span class="h2">Effusive-constrictive pericarditis</span><span class="headingEndMark"> — </span>Effusive-constrictive pericarditis is a clinical syndrome caused by pericardial effusion (often with cardiac tamponade) and concurrent constrictive pericarditis. This syndrome overlaps with transient constrictive pericarditis and is diagnosed by hemodynamic evaluation during pericardial fluid removal by failure of the right atrial pressure to fall by 50 percent or to &lt;10 mmHg after pericardial fluid removal [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/140205.html" rel="external">"Constrictive pericarditis: Clinical features and causes", section on 'Effusive-constrictive pericarditis'</a>.)</p><p>This condition is treated with pericardial fluid drainage (generally pericardiocentesis) followed by medical therapy for transient constrictive pericarditis. If chronic constrictive pericarditis develops, it is usually treated with pericardiectomy. (See <a class="local">'Management of constrictive pericarditis'</a> below.)</p><p class="headingAnchor" id="H3109062399"><span class="h2">Diagnosis of constrictive pericarditis</span><span class="headingEndMark"> — </span>The diagnosis of constrictive pericarditis is often made by echocardiography, with additional evaluation by cardiovascular magnetic resonance (CMR) imaging and/or cardiac computed tomography (CT) and occasional need for invasive cardiac catheterization  (<a class="graphic graphic_algorithm graphicRef141074" href="/z/d/graphic/141074.html" rel="external">algorithm 4</a>). (See  <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation"</a>.)</p><p>On echocardiography, respirophasic ventricular septal shift, plus either or both of hepatic vein diastolic flow reversal ratio ≥79 percent and medial e' velocity ≥9 cm/s is generally sufficient to confirm a diagnosis of constrictive pericarditis  (<a class="graphic graphic_algorithm graphicRef141074" href="/z/d/graphic/141074.html" rel="external">algorithm 4</a>).</p><p>Although the presence of increased pericardial thickness (best seen on cardiac CT or CMR imaging) suggests the presence of constrictive pericarditis, this finding is not sufficient to establish a diagnosis of constrictive pericarditis, and absence of pericardial thickening does not exclude the presence of constrictive pericarditis. (See  <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation", section on 'Additional testing'</a>.)</p><p class="headingAnchor" id="H1948352717"><span class="h2">Management of constrictive pericarditis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For early disease</strong> – The presence of chest pain, elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), pericardial effusion, and pericardial delayed hyperenhancement on CMR suggests a subacute process that may respond to antiinflammatory therapy. Doses of antiinflammatory agents are the same as those used for acute pericarditis, but the duration of therapy is generally longer for constrictive pericarditis  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 5</a> and <a class="graphic graphic_algorithm graphicRef141073" href="/z/d/graphic/141073.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/z/d/html/140886.html" rel="external">"Constrictive pericarditis: Management and prognosis", section on 'Treatment of early (subacute) disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For chronic constriction</strong> – Pericardiectomy is the only definitive treatment for patients with late (chronic) constrictive pericarditis  (<a class="graphic graphic_algorithm graphicRef141073" href="/z/d/graphic/141073.html" rel="external">algorithm 3</a>), but the procedure is associated with significant operative risk. Pericardiectomy involves removal of as much of the constricting parietal and epicardial (visceral) layers as possible, including layers over the right atrium, superior vena cava, inferior vena cava, and the inferior part of the right ventricle adjacent to the diaphragm, while preserving the bilateral phrenic nerves. Diuretic therapy is used only as a temporizing measure and for patients who are not candidates for surgery. (See  <a class="medical medical_review" href="/z/d/html/140886.html" rel="external">"Constrictive pericarditis: Management and prognosis", section on 'Treatment of late (chronic) disease'</a>.)</p><p></p><p class="bulletIndent1">Pericardiectomy is reserved for patients who meet all of the following criteria:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms and signs have persisted despite at least 4 to 12 months of antiinflammatory therapy  (<a class="graphic graphic_algorithm graphicRef141073" href="/z/d/graphic/141073.html" rel="external">algorithm 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms are moderate to severe (New York Heart Association functional class III or IV  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 7</a>)).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Constrictive pericarditis has not progressed to "end-stage." Manifestations of end-stage disease can include cachexia, markedly reduced resting cardiac output (cardiac index ≤1.2 L/m<sup>2</sup> per min), hypoalbuminemia due to protein-losing enteropathy, and/or congestive hepatopathy including cardiac cirrhosis. (See  <a class="medical medical_review" href="/z/d/html/3592.html" rel="external">"Congestive hepatopathy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no concomitant restrictive cardiomyopathy (eg, due to radiation-induced injury). (See  <a class="medical medical_review" href="/z/d/html/4918.html" rel="external">"Restrictive cardiomyopathies"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There are no other comorbid conditions that would place the patient at high risk (eg, end-stage kidney disease or ventricular systolic dysfunction).</p><p></p><p class="headingAnchor" id="H1445721972"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116655.html" rel="external">"Society guideline links: Pericardial disease"</a>.)</p><p class="headingAnchor" id="H939345565"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Pericardial syndromes are classified according to clinical features, time course, and etiology  (<a class="graphic graphic_table graphicRef67851" href="/z/d/graphic/67851.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef61171" href="/z/d/graphic/61171.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute and recurrent pericarditis - </strong>Acute pericarditis is a condition lasting less than four to six weeks with at least two of four diagnostic features  (<a class="graphic graphic_table graphicRef74376" href="/z/d/graphic/74376.html" rel="external">table 3</a>). While most patients with acute idiopathic or viral pericarditis have a good long-term prognosis, a minority of patients develop recurrent, incessant, or chronic disease and are at risk for developing constrictive pericarditis. (See <a class="local">'Acute pericarditis'</a> above.)</p><p></p><p class="bulletIndent1">Management of acute or recurrent pericarditis includes therapy directed at the disease process or cause (if known)  (<a class="graphic graphic_algorithm graphicRef114845" href="/z/d/graphic/114845.html" rel="external">algorithm 1</a>). Most patients with acute or recurrent pericarditis are treated with antiinflammatory agents  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 5</a>). (See <a class="local">'Management of pericarditis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pericardial effusion</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urgent conditions</strong> – The following conditions require urgent diagnosis and pericardial fluid removal  (<a class="graphic graphic_algorithm graphicRef143187" href="/z/d/graphic/143187.html" rel="external">algorithm 2</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cardiac tamponade</strong> (pericardial fluid accumulating under pressure and impairing cardiac filling) presents with symptoms such as fatigue, dyspnea, and syncope and signs such as sinus tachycardia, elevated jugular venous pressure, pulsus paradoxus, and hypotension. The size of the pericardial effusion is commonly moderate or large but may be relatively small if the fluid has accumulated rapidly  (<a class="graphic graphic_figure graphicRef75068" href="/z/d/graphic/75068.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Purulent pericarditis</strong> (defined as infection with macroscopically or microscopically purulent pericardial fluid) typically presents with high fever and tachycardia with or without chest pain, often in the setting of predisposing conditions. It is caused by bacterial (including tuberculous) or fungal infection and is treated with urgent pericardial fluid removal and antimicrobial therapy (See  <a class="medical medical_review" href="/z/d/html/2128.html" rel="external">"Purulent pericarditis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonurgent conditions</strong> – Patients who do not require immediate pericardial fluid drainage are monitored; some may undergo pericardial fluid sampling for diagnostic purposes  (<a class="graphic graphic_algorithm graphicRef143187" href="/z/d/graphic/143187.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis", section on 'Pericardial fluid analysis and biopsy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pericardial drainage</strong> – When pericardial fluid drainage is indicated, this is usually performed by percutaneous drainage unless the fluid is inaccessible or there is a critical cardiac or aortic bleeding site that requires surgical management  (<a class="graphic graphic_algorithm graphicRef143187" href="/z/d/graphic/143187.html" rel="external">algorithm 2</a>) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reaccumulation</strong> – For patients deemed at high risk for recurrent pericardial effusion (including those with malignant pericardial effusion or purulent pericarditis), initial management with pericardial fluid removal may be combined with or followed by one or more measures to prevent or treat recurrent pericardial effusion, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/143123.html" rel="external">"Pericardial effusion: Approach to management"</a> and  <a class="medical medical_review" href="/z/d/html/141940.html" rel="external">"Pericardial disease associated with cancer: Management", section on 'Prevention and treatment of recurrent malignant pericardial effusion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constrictive pericarditis</strong> – Constrictive pericarditis is a clinical syndrome in which an inelastic thickened pericardium restricts cardiac filling. Patients with constrictive pericarditis typically present months to years after an initial insult involving the pericardium. (See  <a class="medical medical_review" href="/z/d/html/140205.html" rel="external">"Constrictive pericarditis: Clinical features and causes"</a>.)</p><p></p><p class="bulletIndent1">Diagnosis is often made by echocardiography with additional cardiac testing as needed  (<a class="graphic graphic_algorithm graphicRef141074" href="/z/d/graphic/141074.html" rel="external">algorithm 4</a>). (See  <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation"</a>.)</p><p></p><p class="bulletIndent1">A minority of cases of constrictive pericarditis are transient with resolution within two to six months spontaneously or with medical therapy  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 5</a> and <a class="graphic graphic_algorithm graphicRef141073" href="/z/d/graphic/141073.html" rel="external">algorithm 3</a>). Most constrictive pericarditis has a chronic course for which pericardiectomy is the only definitive treatment. (See  <a class="medical medical_review" href="/z/d/html/140886.html" rel="external">"Constrictive pericarditis: Management and prognosis"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36:2921.</a></li><li class="breakAll">Spodick DH. Pericardial disease. In: Heart Disease: A Textbook of Cardiovascular Medicine, Braunwald E, Zipes D, Libby P (Eds), Saunders, New York 2001. p.183.</li><li><a class="nounderline abstract_t">Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet 2004; 363:717.</a></li><li><a class="nounderline abstract_t">Caforio AL, Brucato A, Doria A, et al. Anti-heart and anti-intercalated disk autoantibodies: evidence for autoimmunity in idiopathic recurrent acute pericarditis. Heart 2010; 96:779.</a></li><li><a class="nounderline abstract_t">Maestroni S, Di Corato PR, Cumetti D, et al. Recurrent pericarditis: autoimmune or autoinflammatory? Autoimmun Rev 2012; 12:60.</a></li><li><a class="nounderline abstract_t">Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 75:76.</a></li><li><a class="nounderline abstract_t">Andreis A, Imazio M, Casula M, et al. Recurrent pericarditis: an update on diagnosis and management. Intern Emerg Med 2021; 16:551.</a></li><li><a class="nounderline abstract_t">Soler-Soler J, Sagristà-Sauleda J, Permanyer-Miralda G. Relapsing pericarditis. Heart 2004; 90:1364.</a></li><li><a class="nounderline abstract_t">Alabed S, Cabello JB, Irving GJ, et al. Colchicine for pericarditis. Cochrane Database Syst Rev 2014; :CD010652.</a></li><li><a class="nounderline abstract_t">Welch TD. Constrictive pericarditis: diagnosis, management and clinical outcomes. Heart 2018; 104:725.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation 2011; 124:1270.</a></li></ol></div><div id="topicVersionRevision">Topic 143126 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320112" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320112" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15001332" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20448129" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Anti-heart and anti-intercalated disk autoantibodies: evidence for autoimmunity in idiopathic recurrent acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22884556" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recurrent pericarditis: autoimmune or autoinflammatory?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31918837" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33641044" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Recurrent pericarditis: an update on diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486149" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Relapsing pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25164988" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Colchicine for pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29175978" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Constrictive pericarditis: diagnosis, management and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844077" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk of constrictive pericarditis after acute pericarditis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
